标题
Developing biomarkers to predict benefit from HGF/MET pathway inhibitors
作者
关键词
-
出版物
JOURNAL OF PATHOLOGY
Volume 232, Issue 2, Pages 210-218
出版商
Wiley
发表日期
2013-10-08
DOI
10.1002/path.4268
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses.
- (2017) C. Eng et al. JOURNAL OF CLINICAL ONCOLOGY
- Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.
- (2017) D. R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
- (2013) R. Katayama et al. CANCER RESEARCH
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
- (2013) C. Basilico et al. CLINICAL CANCER RESEARCH
- HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
- (2013) E. Penuel et al. MOLECULAR CANCER THERAPEUTICS
- Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
- (2013) Manish A. Shah et al. PLoS One
- Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
- (2012) C. J. Ryan et al. CLINICAL CANCER RESEARCH
- Quality really matters: the need to improve specimen quality in biomedical research
- (2012) Daniel Simeon-Dubach et al. HISTOPATHOLOGY
- Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
- (2012) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer
- (2012) Rafal Dziadziuszko et al. Journal of Thoracic Oncology
- Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
- (2012) W. Okamoto et al. MOLECULAR CANCER THERAPEUTICS
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
- (2012) Alex Kentsis et al. NATURE MEDICINE
- MET: a promising anticancer therapeutic target
- (2012) Solange Peters et al. Nature Reviews Clinical Oncology
- MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines
- (2011) E Arriola et al. BRITISH JOURNAL OF CANCER
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Activation of theMETPathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer
- (2011) Francesco Graziano et al. JOURNAL OF CLINICAL ONCOLOGY
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor
- (2011) Andrew S. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatocyte growth factor twenty years on: Much more than a growth factor
- (2011) Takahiro Nakamura et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Standardized Assessment of the HER2 Status in Breast Cancer by Immunohistochemistry
- (2011) David G. Hicks et al. Labmedicine
- A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma
- (2011) P. Y. Wen et al. NEURO-ONCOLOGY
- Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma
- (2011) Q. Xie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence
- (2011) D. V. T. Catenacci et al. Cancer Discovery
- Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
- (2011) Sai-Hong Ignatius Ou Drug Design Development and Therapy
- c-MET as a potential therapeutic target and biomarker in cancer
- (2011) J. Rafael Sierra et al. Therapeutic Advances in Medical Oncology
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- MET Receptor Sequence Variants R970C and T992I Lack Transforming Capacity
- (2010) J. W. Tyner et al. CANCER RESEARCH
- Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
- (2010) M. S. Gordon et al. CLINICAL CANCER RESEARCH
- Clinical implications ofMETgene copy number in lung cancer
- (2010) Luca Toschi et al. Future Oncology
- Biochemical Characterization of AMG 102: A Neutralizing, Fully Human Monoclonal Antibody to Human and Nonhuman Primate Hepatocyte Growth Factor
- (2010) T. L. Burgess et al. MOLECULAR CANCER THERAPEUTICS
- TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non-Small Cell Lung Cancer with an EGFR Mutation
- (2010) W. Okamoto et al. MOLECULAR CANCER THERAPEUTICS
- MET signalling: principles and functions in development, organ regeneration and cancer
- (2010) Livio Trusolino et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer
- (2009) M. G. Ponzo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer
- (2008) Katsuhiro Okuda et al. CANCER SCIENCE
- EGF and HGF levels are increased during active HBV infection and enhance survival signaling through extracellular matrix interactions in primary human hepatocytes
- (2008) Ana Paula Barreiros et al. INTERNATIONAL JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More